期刊
LANCET
卷 376, 期 9746, 页码 1094-1108出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)60826-4
关键词
-
资金
- Merck Sharp and Dhome
- Pfizer
- Novartis
- Roche
- Wyeth
- Schering Plough
- Bristol-Myers Squibb
- UCB
- Centocor
- Biotest AG
- Sanofi-Aventis
- Abbott
- Axis-Shield diagnostics
- European Union [223404]
- Dutch Arthritis Association
- National Institute for Health Research [NF-SI-0507-10104] Funding Source: researchfish
Rheumatoid arthritis is characterised by persistent synovitis, systemic inflammation, and autoantibodies (particularly to rheumatoid factor and citrullinated peptide). 50% of the risk for development of rheumatoid arthritis is attributable to genetic factors. Smoking is the main environmental risk. In industrialised countries, rheumatoid arthritis affects 0.5-1.0% of adults, with 5-50 per 100 000 new cases annually. The disorder is most typical in women and elderly people. Uncontrolled active rheumatoid arthritis causes joint damage, disability, decreased quality of life, and cardiovascular and other comorbidities. Disease-modifying antirheumatic drugs (DMARDs), the key therapeutic agents, reduce synovitis and systemic inflammation and improve function. The leading DMARD is methotrexate, which can be combined with other drugs of this type. Biological agents are used when arthritis is uncontrolled or toxic effects arise with DMARDs. Tumour necrosis factor inhibitors were the first biological agents, followed by abatacept, rituximab, and tocilizumab. Infections and high costs restrict prescription of biological agents. Long-term remission induced by intensive, short-term treatment selected by biomarker profiles is the ultimate goal.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据